These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: New marker of bone resorption: hydroxyproline-containing peptide. High-performance liquid chromatographic assay without hydrolysis as an alternative to hydroxyproline determination: a preliminary report.
    Author: Mazzi G, Fioravanzo F, Burti E.
    Journal: J Chromatogr B Biomed Appl; 1996 Apr 12; 678(2):165-72. PubMed ID: 8738018.
    Abstract:
    A high-performance liquid chromatographic (HPLC) assay for a urinary hydroxyproline-containing peptide (hydroxy-proline peptide, HypP) is described. This peptide represents about 50% of urinary hydroxyproline-containing peptides. Its concentration and total 4-hydroxyproline (Hyp) concentration evaluated in 325 urine samples have been shown to be closely correlated (r = 0.972; y = 0.499 x -1.5), which may indicate that the two markers provide the same information. The HypP assay, similar to Hyp assay, is carried out without hydrolysis of urine samples. After the blocking of primary amino acids by o-phthaldialdehyde (OPA) and derivatization of secondary amino acids by 9-fluorenylmethyl chloroformate (FMOC-CI), the FMOC derivatives of HypP and 3,4-dehydroproline (internal standard) were separated on a strong anion-exchange column and detected fluorimetrically. HypP concentration was calculated by measurement of peak-area ratios of HypP and the hydroxyproline standard. The HypP/creatinine (mmol/mol) ratio in fasting urine samples from healthy adults was found to be 8.2 (S.D. = 1.6, n = 33) in 27-44-year-old premenopausal women and 6.9 (S.D. = 1.7, n = 21) in 28-49-year-old men.
    [Abstract] [Full Text] [Related] [New Search]